Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have been given an average recommendation of “Buy” by the seven brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $25.83.

A number of equities research analysts have recently issued reports on CNTA shares. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $17.07 on Friday. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The business’s fifty day moving average is $16.77 and its two-hundred day moving average is $15.65. The stock has a market capitalization of $2.25 billion, a P/E ratio of -11.16 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52.

Insider Buying and Selling

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $17.66, for a total value of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares of the company’s stock, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total value of $30,479.04. Following the sale, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,500,056.64. The trade was a 0.29 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 452,652 shares of company stock valued at $7,800,532. Corporate insiders own 11.59% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new position in Centessa Pharmaceuticals during the third quarter valued at approximately $20,698,000. Foresite Capital Management VI LLC bought a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at $20,994,000. Franklin Resources Inc. raised its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after purchasing an additional 953,659 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after purchasing an additional 924,027 shares in the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.